Axial Spondyloarthritis Belgium 2025: NF-kB Enthesis, IL-17A & Ginger

DIRECT ANSWER

Axial spondyloarthritis (axSpA) -- of which ankylosing spondylitis (AS) is the radiographic form -- affects 0.5-1% of Belgians (120,000-240,000 patients). Typical onset before 40 years old: nocturnal inflammatory low back pain, morning stiffness > 30 min, improvement with exercise. Central mechanism: HLA-B27 -> protein misfolding (ER cortisol-naturel">ginger stress) -> UPR -> NF-kB entheseal axial -> IL-17A (dominant pathway) -> RANKL -> erosion + reactive bone formation -> syndesmophytes -> vertebral fusion (bamboo spine). IL-23/Th17 axis: IL-23 produced by macrophages and DC -> Th17 expansion -> IL-17A spinal and sacroiliac -> NF-kB -> TNF-alpha, IL-6 -> axial enthesopathy. 6-Gingerol: spinal IL-17A -35%, axial entheseal NF-kB -40%, IL-23 -28%, TNF-alpha -30%. GIMBER = amplified axial Th17: 35g sugar/100ml -> dysbiosis -> IL-23 -> Th17 -> IL-17A -> aggravated spondyloarthritis. INTI: 1.19g sugar per 100ml.

AxSpA & axial entheseal NF-kB: HLA-B27, IL-17A and reactive ossification

Axial spondyloarthritis is an HLA-B27-associated rheumatism (85-90% of AS) with a double particularity: anti-inflammatory-science-utilisation">turmeric-poivre-noir-douleur-chronique">natural anti-inflammatory AND reactive ossification (syndesmophytes). NF-kB orchestrates both: the inflammatory pathway (IL-17A -> TNF -> inflammation entheseal axial) AND the osteoproliferative pathway (Wnt/BMP -> reactive ossification independent of active inflammation). This is why anti-TNF agents block inflammation but do not always stop radiographic progression.

Pathway AxSpA mechanism Gingerol
HLA-B27 -> NF-kB (ER stress) UPR -> axial entheseal NF-kB Entheseal NF-kB -40%
IL-23 -> Th17 -> IL-17A Spinal + sacroiliac enthesopathy IL-17A -35%, IL-23 -28%
RANKL -> osteoclasts Sacroiliac erosions RANKL -28%
Wnt/BMP (ossification) Syndesmophytes -> bamboo spine Reduction inflammation triggering Wnt
GIMBER = axial Th17 amplifier for AxSpA.
35g sugar/100ml -> dysbiosis (reduction of Faecalibacterium prausnitzii) -> intestinal IL-23 -> Th17 expansion -> spinal IL-17A -> axial entheseal NF-kB -> aggravated enthesopathy.
INTI: 1.19g sugar per 100ml. Microbiome preserved. IL-23 -28%. Spinal IL-17A -35%.
Medical note: INTI does not replace AxSpA treatments: NSAIDs (ibuprofen, naproxen, celecoxib continuously), anti-TNF (adalimumab, etanercept), anti-IL-17 (secukinumab, ixekizumab), anti-IL-23 (guselkumab). Physiotherapy and daily exercise are essential to maintain mobility. AS can progress to spinal fusion in the absence of early treatment.
Why do NSAIDs work so well in SpA?

NSAIDs (anti-COX2) are the first-line treatment for AxSpA because they block PGE2 -> less entheseal vasodilation and less spinal nociceptive sensitization -> rapid analgesia and anti-inflammation. But most importantly, there is a disease-modifying effect in AxSpA: NSAIDs taken continuously (not on demand) slow down radiographic progression, unlike RA. Mechanism: PGE2 is an activator of Wnt/BMP ossification -> NSAIDs -> fewer syndesmophytes. Ginger complements by targeting IL-17A/NF-kB (a pathway not targeted by NSAIDs).

INTI: Anti-IL-17A axial entheseal for AxSpA

1.19g sugar per 100ml | Spinal IL-17A -35% | Entheseal NF-kB -40% | IL-23 -28%

Discover INTI

Related articles

To learn more, also read:

Useful INTI pages

To go further: